The aberrant activation of the SHH signaling pathway exhibits significant heterogeneity in bladder cancer, characterized primarily by dysregulated activation of the Gli transcription factor family (particularly Gli3) and imbalance in non-coding RNA regulation. This evidence concerns the gene GLI1 and urinary bladder cancer.